 [1m([0morchestrator-mortality after myocardial infarction-DESIPRAMINE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes DESIPRAMINE increase or decrease the risk [0m
[34mof mortality after myocardial infarction?[0m
 [1m([0morchestrator-mortality after myocardial infarction-DESIPRAMINE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-mortality after myocardial infarction-DESIPRAMINE[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-mortality after myocardial infarction-DESIPRAMINE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"DESIPRAMINE"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-mortality after myocardial infarction-DESIPRAMINE[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDESIPRAMINE[0m
 [1m([0morchestrator-mortality after myocardial infarction-DESIPRAMINE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-mortality after myocardial infarction-DESIPRAMINE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-mortality after myocardial infarction-DESIPRAMINE[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDESIPRAMINE[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Provide information about Desipramine."[0m[32m,[0m
[32m    [0m[32m"filter_drugs"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"Desipramine"[0m
[32m    [0m[1;32m][0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Below are some relevant extracts for your query:[0m
[31m        -----[0m
[31m        [0m
[31mCONTENT: DESIPRAMINE: precautions: PRECAUTIONS Information for Patients Prescribers or other health professionals should inform patients, their families, and their caregivers about the benefits and [0m
[31mrisks associated with treatment with desipramine hydrochloride and should counsel them in its appropriate use. A patient Medication Guide about [0m[31m"Antidepressant Medicines, Depression and other Serious [0m
[31mMental illnesses, and Suicidal Thoughts or Actions"[0m[31m is available for desipramine hydrochloride. The prescriber or health professional should instruct patients, their families, and their caregivers to [0m
[31mread the Medication Guide and should assist them in understanding its contents. Patients should be given the opportunity to discuss the contents of the Medication Guide and to obtain answers to any [0m
[31mquestions they may have. The complete text of the Medication Guide is reprinted at the end of this document. Patients should be advised of the following issues and asked to alert their prescriber if [0m
[31mthese occur while taking desipramine hydrochloride. DESIPRAMINE: precautions: Clinical Worsening and Suicide Risk: Patients, their families, and their caregivers should be encouraged to be alert to [0m
[31mthe emergence of anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia [0m[1;31m([0m[31mpsychomotor restlessness[0m[1;31m)[0m[31m, hypomania, mania, other unusual changes in [0m
[31mbehavior, worsening of depression, and suicidal ideation, especially early during antidepressant treatment and when the dose is adjusted up or down. Families and caregivers of patients should be [0m
[31madvised to observe for the emergence of such symptoms on a day-to-day basis, since changes may be abrupt. Such symptoms should be reported to the patient's prescriber or health professional, [0m
[31mespecially if they are severe, abrupt in onset, or were not part of the patient's presenting symptoms. Symptoms such as these may be associated with an increased risk for suicidal thinking and [0m
[31mbehavior and indicate a need for very close monitoring and possibly changes in the medication. DESIPRAMINE: precautions: Patients should be advised that taking desipramine hydrochloride can cause mild[0m
[31mpupillary dilation, which in susceptible individuals, can lead to an episode of angle closure glaucoma. Pre-existing glaucoma is almost always open-angle glaucoma because angle closure glaucoma, when [0m
[31mdiagnosed, can be treated definitively with iridectomy. Open- angle glaucoma is not a risk factor for angle closure glaucoma. Patients may wish to be examined to determine whether they are susceptible[0m
[31mto angle closure, and have a prophylactic procedure [0m[1;31m([0m[31me.g., iridectomy[0m[1;31m)[0m[31m, if they are susceptible. Pediatric Use Safety and effectiveness in the pediatric population have not been established [0m[1;31m([0m[31m see BOX [0m
[31mWARNING and WARNINGS-Clinical Worsening and Suicide Risk [0m[1;31m)[0m[31m. Therefore, desipramine hydrochloride is not recommended for use in children. DESIPRAMINE: precautions: Anyone considering the use of [0m
[31mdesipramine hydrochloride in a child or adolescent must balance the potential risks with the clinical need [0m[1;31m([0m[31msee also ADVERSE REACTIONS- Cardiovascular [0m[1;31m)[0m[31m. General It is important that this drug be [0m
[31mdispensed in the least possible quantities to depressed outpatients, since suicide has been accomplished with this class of drug [0m[1;31m([0m[31m see WARNINGS-Clinical Worsening and Suicide Risk [0m[1;31m)[0m[31m. Ordinary prudence[0m
[31mrequires that children not have access to this drug or to potent drugs of any kind; if possible, this drug should be dispensed in containers with child-resistant safety closures. Storage of this drug [0m
[31min the home must be supervised responsibly. If serious adverse effects occur, dosage should be reduced or treatment should be altered. Desipramine hydrochloride therapy in patients with [0m
[31mmanic-depressive illness may induce a hypomanic state after the depressive phase terminates. The drug may cause exacerbation of psychosis in schizophrenic patients. Both elevation and lowering of [0m
[31mblood sugar levels have been reported. DESIPRAMINE: precautions: Leukocyte and differential counts should be performed in any patient who develops fever and sore throat during therapy; the drug should[0m
[31mbe discontinued if there is evidence of pathologic neutrophil depression. Clinical experience in the concurrent administration of ECT and antidepressant drugs is limited. Thus, if such treatment is [0m
[31messential, the possibility of increased risk relative to benefits should be considered. This drug should be discontinued as soon as possible prior to elective surgery because of possible [0m
[31mcardiovascular effects. Hypertensive episodes have been observed during surgery in patients taking desipramine hydrochloride.         [0m
[31mSOUR[0m[1;31mCE:DE[0m[31mSIPRAMINE label[0m


[31mCONTENT: DESIPRAMINE: boxed_warning: Suicidality and Antidepressant Drugs Antidepressants increased the risk compared to placebo of suicidal thinking and behavior [0m[1;31m([0m[31msuicidality[0m[1;31m)[0m[31m in children, [0m
[31madolescents, and young adults in short-term studies of major depressive disorder [0m[1;31m([0m[31mMDD[0m[1;31m)[0m[31m and other psychiatric disorders. Anyone considering the use of desipramine hydrochloride tablets or any other [0m
[31mantidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. Short-term studies did not show an increase in the risk of suicidality with antidepressants [0m
[31mcompared to placebo in adults beyond age [0m[1;31m24[0m[31m; there was a reduction in risk with antidepressants compared to placebo in adults aged [0m[1;31m65[0m[31m and older. Depression and certain other psychiatric disorders are [0m
[31mthemselves associated with increases in the risk of suicide. Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely for clinical [0m
[31mworsening, suicidality, or unusual changes in behavior. DESIPRAMINE: boxed_warning: Families and caregivers should be advised of the need for close observation and communication with the prescriber. [0m
[31mDesipramine hydrochloride is not approved for use in pediatric patients [0m[1;31m([0m[31m See WARNINGS: Clinical Worsening and Suicide Risk , PRECAUTIONS: Information for Patients , and PRECAUTIONS: Pediatric Use .  [0m
[31mSOUR[0m[1;31mCE:DE[0m[31mSIPRAMINE label[0m


[31mCONTENT: DESIPRAMINE: spl_medguide: MEDICATION GUIDE Desipramine Hydrochloride Tablets, USP [0m[1;31m([0m[31mdes-IP-ra-meen HYE-droe-KLOR-ide[0m[1;31m)[0m[31m Antidepressant Medicines, Depression and other Serious Mental Illnesses, [0m
[31mand Suicidal Thoughts or Actions Read the Medication Guide that comes with your, or your family member's, antidepressant medicine. This Medication Guide is only about the risk of suicidal thoughts and[0m
[31mactions with antidepressant medicines. Talk to your, or your family member's, healthcare provider about: all risks and benefits of treatment with antidepressant medicines all treatment choices for [0m
[31mdepression or other serious mental illness What is the most important information I should know about antidepressant medicines, depression and other serious mental illnesses, and suicidal thoughts or [0m
[31mactions? Antidepressant medicines may increase suicidal thoughts or actions in some children, teenagers, and young adults within the first few months of treatment. Depression and other serious mental [0m
[31millnesses are the most important causes of suicidal thoughts and actions. DESIPRAMINE: spl_medguide: Some people may have a particularly high risk of having suicidal thoughts or actions. These include[0m
[31mpeople who have [0m[1;31m([0m[31mor have a family history of[0m[1;31m)[0m[31m bipolar illness [0m[1;31m([0m[31malso called manic- depressive illness[0m[1;31m)[0m[31m or suicidal thoughts or actions. How can I watch for and try to prevent suicidal thoughts and [0m
[31mactions in myself or a family member? Pay close attention to any changes, especially sudden changes, in mood, behaviors, thoughts, or feelings.This is very important when an antidepressant medicine is[0m
[31mstarted or when the dose is changed. Call the healthcare provider right away to report new or sudden changes in mood, behavior, thoughts, or feelings. Keep all follow-up visits with the healthcare [0m
[31mprovider as scheduled. Call the healthcare provider between visits as needed, especially if you have concerns about symptoms. Who should not take desipramine hydrochloride tablets, USP? You should not[0m
[31mtake desipramine hydrochloride tablets, USP if you take a monoamine oxidase inhibitor [0m[1;31m([0m[31mMAOI[0m[1;31m)[0m[31m. DESIPRAMINE: spl_medguide: Ask your healthcare provider or pharmacist if you are not sure if you take an [0m
[31mMAOI, including the antibiotic linezolid. Do not take an MAOI within [0m[1;31m2[0m[31m weeks of stopping desipramine hydrochloride tablets, USP unless directed to do so by your physician. Do not start desipramine [0m
[31mhydrochloride tablets, USP if you stopped taking an MAOI in the last [0m[1;31m2[0m[31m weeks unless directed to do so by your physician. DESIPRAMINE: spl_medguide: Call a healthcare provider right away if you or your[0m
[31mfamily member has any of the following symptoms, especially if they are new, worse, or worry you: thoughts about suicide or dying attempts to commit suicide new or worse depression new or worse [0m
[31manxiety feeling very agitated or restless panic attacks trouble sleeping [0m[1;31m([0m[31minsomnia[0m[1;31m)[0m[31m new or worse irritability acting aggressive, being angry, or violent acting on dangerous impulses an extreme [0m
[31mincrease in activity and talking [0m[1;31m([0m[31mmania[0m[1;31m)[0m[31m other unusual changes in behavior or mood Visual Problems eye pain changes in vision swelling or redness in or around the eye Only some people are at risk for [0m
[31mthese problems. You may want to undergo an eye examination to see if you are at risk and receive preventative treatment if you are. What else do I need to know about antidepressant medicines? Never [0m
[31mstop an antidepressant medicine without first talking to a healthcare provider. Stopping an antidepressant medicine suddenly can cause other symptoms. Antidepressants are medicines used to treat [0m
[31mdepression and other illnesses . DESIPRAMINE: spl_medguide: It is important to discuss all the risks of treating depression and also the risks of not treating it. Patients and their families or other [0m
[31mcaregivers should discuss all treatment choices with the healthcare provider, not just the use of antidepressants. Antidepressant medicines have other side effects . Talk to the healthcare provider [0m
[31mabout the side effects of the medicine prescribed for you or your family member. Antidepressant medicines can interact with other medicines . Know all of the medicines that you or your family member [0m
[31mtakes. Keep a list of all medicines to show the healthcare provider. Do not start new medicines without first checking with your healthcare provider. Not all antidepressant medicines prescribed for [0m
[31mchildren are FDA approved for use in children . Talk to your child's healthcare provider for more information. Tell your healthcare provider if you are pregnant or plan to become pregnant during [0m
[31mtreatment with desipramine hydrochloride tablets, USP. DESIPRAMINE: spl_medguide: If you become pregnant during treatment with desipramine hydrochloride tablets USP, talk to your healthcare provider [0m
[31mabout registering with the National Pregnancy Registry for Antidepressants. You can register by calling [0m[1;31m1[0m[31m-[0m[1;31m844[0m[31m-[0m[1;31m405[0m[31m- [0m[1;31m6185[0m[31m or visit [0m[4;31mhttp://womensmentalhealth.org/clinical-and-[0m[31m research- [0m
[31mprograms/pregnancyregistry/antidepressants Call your doctor for medical advice about side effects. You may report side effects to FDA at [0m[1;31m1800[0m[31m-FDA-[0m[1;31m1088[0m[31m. You may also report side effects to Chartwell [0m
[31mRX, LLC. at [0m[1;31m1[0m[31m-[0m[1;31m845[0m[31m-[0m[1;31m232[0m[31m-[0m[1;31m1683[0m[31m. This Medication Guide has been approved by the U.S. Food and Drug Administration for all antidepressants. Manufactured By: USV Private Limited Daman - [0m[1;31m396210[0m[31m, India [0m
[31mManufactured For: Chartwell RX, LLC. DESIPRAMINE: spl_medguide: Congers, NY [0m[1;31m10920[0m[31m Revised: [0m[1;31m04[0m[31m/[0m[1;31m2023[0m[31m L71459         [0m
[31mSOUR[0m[1;31mCE:DE[0m[31mSIPRAMINE label[0m


[31mCONTENT: DESIPRAMINE: adverse_reactions: ADVERSE REACTIONS Included in the following listing are a few adverse reactions that have not been reported with this specific drug. However, the pharmacologic[0m
[31msimilarities among the tricyclic antidepressant drugs require that each of the reactions be considered when desipramine hydrochloride is given. Cardiovascular: Hypotension, hypertension, palpitations,[0m
[31mheart block, myocardial infarction, stroke, arrhythmias, premature ventricular contractions, tachycardia, ventricular tachycardia, ventricular fibrillation, sudden death There has been a report of an [0m
[31m"acute collapse"[0m[31m and [0m[31m"sudden death"[0m[31m in an [0m[1;31m8[0m[31m-year-old [0m[1;31m([0m[1;31m18[0m[31m kg[0m[1;31m)[0m[31m male, treated for [0m[1;31m2[0m[31m years for hyperactivity. DESIPRAMINE: adverse_reactions: There have been additional reports of sudden death in children[0m
[1;31m([0m[31m See PRECAUTIONS- Pediatric Use [0m[1;31m)[0m[31m Psychiatric: Confusional states [0m[1;31m([0m[31mespecially in the elderly[0m[1;31m)[0m[31m with hallucinations, disorientation, delusions; anxiety, restlessness, agitation; insomnia and [0m
[31mnightmares; hypomania; exacerbation of psychosis Neurologic: Numbness, tingling, paresthesias of extremities; incoordination, ataxia, tremors; peripheral neuropathy; extrapyramidal symptoms; seizures;[0m
[31malterations in EEG patterns; tinnitus . Symptoms attributed to Neuroleptic Malignant Syndrome have been reported during desipramine use with and without concomitant neuroleptic therapy. DESIPRAMINE: [0m
[31madverse_reactions: Anticholinergic: Dry mouth, and rarely associated sublingual adenitis; blurred vision, disturbance of accommodation, mydriasis, increased intraocular pressure; constipation, [0m
[31mparalytic ileus; urinary retention, delayed micturition, dilation of urinary tract Allergic: Skin rash, petechiae, urticaria, itching, photosensitization [0m[1;31m([0m[31mavoid excessive exposure to sunlight[0m[1;31m)[0m[31m, edema [0m
[1;31m([0m[31mof face and tongue or general[0m[1;31m)[0m[31m, drug fever, cross- sensitivity with other tricyclic drugs Hematologic: Bone marrow depressions including agranulocytosis, eosinophilia, purpura, thrombocytopenia [0m
[31mGastrointestinal: Anorexia, nausea and vomiting, epigastric distress, peculiar taste, abdominal cramps, diarrhea, stomatitis, black tongue, hepatitis, jaundice [0m[1;31m([0m[31msimulating obstructive[0m[1;31m)[0m[31m, altered liver [0m
[31mfunction, elevated liver function tests, increased pancreatic enzymes Endocrine: Gynecomastia         [0m
[31mSOUR[0m[1;31mCE:DE[0m[31mSIPRAMINE label[0m


[31mCONTENT: DESIPRAMINE: description: DESCRIPTION Desipramine hydrochloride, USP is an antidepressant drug of the tricyclic type, and is chemically: 5H-Dibenz [0m[31m [0m
[31mazepine-[0m[1;31m5[0m[31m-propanamine,[0m[1;31m10[0m[31m,[0m[1;31m11[0m[31m-dihydro-N-methyl-, monohydrochloride. Each desipramine hydrochloride, USP tablet contains [0m[1;31m10[0m[31m mg, [0m[1;31m25[0m[31m mg, [0m[1;31m50[0m[31m mg, [0m[1;31m75[0m[31m mg, [0m[1;31m100[0m[31m mg, or [0m[1;31m150[0m[31m mg of desipramine hydrochloride for [0m
[31moral administration. Inactive Ingredients The following inactive ingredients are contained in all dosage strengths: Hypromellose, lactose monohydrate, microcrystalline cellulose, polyethylene glycol, [0m
[31msodium starch glycolate type A [0m[1;31m([0m[31mpotato[0m[1;31m)[0m[31m, stearic acid, talc and titanium dioxide. DESIPRAMINE: description: desipramine-chemical-structure         [0m
[31mSOUR[0m[1;31mCE:DE[0m[31mSIPRAMINE label[0m

[31m        -----[0m
[31m        If NONE of the extracts are relevant, try doing a web search with the[0m
[31m        `relevant_search_extracts` tool/function-call[0m
[31m        [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m
[32mANSWER: Desipramine hydrochloride is an antidepressant drug of the tricyclic type. It is used to treat symptoms of depression and is available in various dosages ranging from [0m[1;32m10[0m[32m mg to [0m[1;32m150[0m[32m mg. Patients[0m
[32mand healthcare providers should be aware of the risk of increased suicidal thoughts and behavior, particularly in children, adolescents, and young adults. It is not approved for pediatric use due to [0m
[32mthe risk of clinical worsening and suicide. Desipramine can cause mild pupillary dilation, which may lead to an episode of angle-closure glaucoma in susceptible individuals. The drug should be used [0m
[32mwith caution in patients with a history of manic-depressive illness, schizophrenia, and those with altered blood sugar levels. Adverse reactions can include cardiovascular issues such as hypotension, [0m
[32mhypertension, and arrhythmias, psychiatric effects like confusion and hallucinations, neurologic symptoms such as tremors and seizures, anticholinergic effects like dry mouth and blurred vision, [0m
[32mallergic reactions, hematologic issues like bone marrow depression, gastrointestinal problems, and endocrine changes like gynecomastia.[0m

[32mSOURCE: DESIPRAMINE label[0m
[32mEXTRACT_START_END: DESIPRAMINE: precautions: PRECAUTIONS Information for Patients Prescribers[0m[32m...[0m[32mhypertensive episodes have been observed during surgery[0m[32m...[0m
*[1m([0morchestrator-mortality after myocardial infarction-DESIPRAMINE[1m)[0m [37m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mANSWER: Desipramine hydrochloride is an [0m
[34mantidepressant drug of the tricyclic type. It is used to treat symptoms of depression and is available in various dosages ranging from [0m[1;34m10[0m[34m mg to [0m[1;34m150[0m[34m mg. Patients and healthcare providers should be [0m
[34maware of the risk of increased suicidal thoughts and behavior, particularly in children, adolescents, and young adults. It is not approved for pediatric use due to the risk of clinical worsening and [0m
[34msuicide. Desipramine can cause mild pupillary dilation, which may lead to an episode of angle-closure glaucoma in susceptible individuals. The drug should be used with caution in patients with a [0m
[34mhistory of manic-depressive illness, schizophrenia, and those with altered blood sugar levels. Adverse reactions can include cardiovascular issues such as hypotension, hypertension, and arrhythmias, [0m
[34mpsychiatric effects like confusion and hallucinations, neurologic symptoms such as tremors and seizures, anticholinergic effects like dry mouth and blurred vision, allergic reactions, hematologic [0m
[34missues like bone marrow depression, gastrointestinal problems, and endocrine changes like gynecomastia.[0m

[34mSOURCE: DESIPRAMINE label[0m
[34mEXTRACT_START_END: DESIPRAMINE: precautions: PRECAUTIONS Information for Patients Prescribers[0m[34m...[0m[34mhypertensive episodes have been observed during surgery[0m[34m...[0m
 [1m([0morchestrator-mortality after myocardial infarction-DESIPRAMINE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-mortality after myocardial infarction-DESIPRAMINE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-mortality after myocardial infarction-DESIPRAMINE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does DESIPRAMINE increase or decrease the risk of mortality after myocardial infarction?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"I asked FDAHandler for information on DESIPRAMINE."[0m[32m,[0m
[32m      [0m[32m"FDAHandler provided information from the DESIPRAMINE label, which includes various precautions and adverse reactions associated with its use."[0m[32m,[0m
[32m      [0m[32m"The information provided by FDAHandler did not specifically mention the risk of mortality after myocardial infarction."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"DO-NOT-KNOW"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-mortality after myocardial infarction-DESIPRAMINE[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0morchestrator-mortality after myocardial infarction-DESIPRAMINE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-mortality after myocardial infarction-DESIPRAMINE[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0morchestrator-mortality after myocardial infarction-DESIPRAMINE[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does DESIPRAMINE increase or decrease the risk of mortality after myocardial infarction?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"I asked FDAHandler for information on DESIPRAMINE."[0m[34m,[0m
[34m      [0m[34m"FDAHandler provided information from the DESIPRAMINE label, which includes various precautions and adverse reactions associated with its use."[0m[34m,[0m
[34m      [0m[34m"The information provided by FDAHandler did not specifically mention the risk of mortality after myocardial infarction."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"DO-NOT-KNOW"[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does DESIPRAMINE increase or decrease the risk of mortality after myocardial infarction?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. I asked FDAHandler for information on DESIPRAMINE.[0m
[1;31m2[0m[31m. FDAHandler provided information from the DESIPRAMINE label, which includes various precautions and adverse reactions associated with its use.[0m
[1;31m3[0m[31m. The information provided by FDAHandler did not specifically mention the risk of mortality after myocardial infarction.[0m
[31m        -----[0m
[31m        Final answer: DO-NOT-KNOW[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m""[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0morchestrator-mortality after myocardial infarction-DESIPRAMINE[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>     AGENT[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m""[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0morchestrator-mortality after myocardial infarction-DESIPRAMINE[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mYour reasoning is valid, no feedback was [0m
[31mprovided.[0m
 [1m([0morchestrator-mortality after myocardial infarction-DESIPRAMINE[1m)[0m [31m Entity.USER [0m
 [1m([0morchestrator-mortality after myocardial infarction-DESIPRAMINE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-mortality after myocardial infarction-DESIPRAMINE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m

[32mThe information provided by FDAHandler from the DESIPRAMINE label did not specifically mention the risk of mortality after myocardial infarction. Therefore, based on the FDA label data, it is not [0m
[32mpossible to determine whether DESIPRAMINE increases or decreases the risk of mortality after myocardial infarction.[0m
